Praxis Precision Medicines discusses ulixacaltamide Essential3 at 2024 Movement Disorders Congress

BOSTON, Sept. 26, 2024 – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a biopharmaceutical company at the clinical stage of development, focuses on transforming genetic insights into therapies for central nervous system (CNS) disorders. These disorders are often marked by an imbalance in neuronal excitation and inhibition. Praxis has recently announced its participation in the Movement Disorders Society (MDS) 2024 International Congress in Philadelphia, Pennsylvania, from September 27 to October 1, 2024.

At the MDS 2024 Congress, Praxis will present significant findings from its Phase 3 clinical program evaluating ulixacaltamide for adults with essential tremor (ET). Essential tremor, a common neurological disorder, causes uncontrollable shaking and can significantly interfere with daily activities.

Praxis will highlight its progress through both a platform presentation and a poster session. The platform presentation, titled "Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide," is scheduled for Saturday, September 28, from 1:30 to 2:30 PM ET in Meeting Room 204C. Additionally, a poster presentation is planned for Sunday, September 29, from 1:00 to 3:00 PM ET in Exhibit Hall A, Poster #641.

After the presentations at MDS 2024, materials will be accessible on the Resources page of the Praxis website.

Ulixacaltamide is a specialized small molecule inhibitor of T-type calcium channels, designed to target and block abnormal neuronal burst firing within the Cerebello-Thalamo-Cortical (CTC) circuit, which is linked to tremor activity. This targeted approach aims to provide a more effective treatment for essential tremor. Ulixacaltamide is the leading program in Praxis's Cerebrum™ small molecule platform and is currently under development for essential tremor treatment.

Praxis Precision Medicines is dedicated to leveraging genetic insights from epilepsies to develop therapies for CNS disorders, characterized by an imbalance in neuronal excitation and inhibition. The company utilizes a proprietary small molecule platform called Cerebrum™ and an antisense oligonucleotide (ASO) platform known as Solidus™. These platforms are based on the understanding of shared biological targets and brain circuits. Praxis has developed a varied CNS portfolio with multiple programs focusing on movement disorders and epilepsy, including four clinical-stage product candidates.